Regarding smoking, the Panel agrees that: (1) in case of never smokers with non-oncogene-addicted NSCLC and PD-L1 ≥ 50%, first-line treatments should rely on chemoimmunotherapy, although this not being pursuable in Italy to date due to regulatory reasons; (2) in case of never smokers with non-oncogene-addicted NSCLC and PD-L1 ≥ 90%, CT should never be used alone, and that first-line treatment should be immunotherapy; however, it would consider first-line chemoimmunotherapy if this was possible regulatory-wise. The gene discussed is CD274; the disease is non-small cell lung carcinoma.